News
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
Happy to share our latest publication about the potential health and economic impact of switching the current 13-valent Pneumococcal Conjugate Vaccine (PCV13) among the Greek paediatric Vaccination programme with higher-valent conjugate vaccines. Find out more at:...
8th Annual HTA Conference
"Health Through Evidence had the pleasure of sponsoring the '8th Annual HTA Conference,' which was held on June 14th in Athens, organized by BOUSSIAS and Health Daily. The main theme of the 2023 HTA conference was the new role that HTA and Νegotiations are called upon...
Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece
Excited to share our latest publication about the cost-effectiveness threshold in Greece. To the best of our knowledge, this is the first study that investigated the use of cost-effectiveness threshold for evaluating pharmacological interventions in Greek...
Happy Easter on behalf of the HTE team !
Rare Disease Day
28 February is Rare Disease Day Today marks Rare Disease Day 2023, the official international awareness-raising campaign for rare diseases which takes place on the last day of February every year. The main objective of the campaign is to raise awareness amongst the...